- Home
- LARK vs ANTX Comparison
LARK vs ANTX Comparison
Compare LARK & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LARK | ANTX |
|---|---|---|
| Founded | 1885 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.0M | 170.6M |
| IPO Year | 2001 | 2022 |
Fundamental Metrics
Financial Performance| Metric | LARK | ANTX |
|---|---|---|
| Price | $27.58 | $4.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 3.5K | ★ 233.5K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 35.84 | 32.56 |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.46 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.43 | $1.00 |
| 52 Week High | $30.80 | $6.91 |
Technical Indicators
Market Signals| Indicator | LARK | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.32 | 61.13 |
| Support Level | $27.01 | $1.06 |
| Resistance Level | $28.76 | $5.14 |
| Average True Range (ATR) | 0.85 | 0.40 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 57.50 | 65.04 |
Price Performance
Historical ComparisonAbout LARK Landmark Bancorp Inc.
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and Southwest Kansas.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.